Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
July 28, 2023 at 08:13 AM EDT
Biogen's all-cash deal is a rare-disease play.
 |
||||||||||||
|
||||||||||||
| About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map | ||||||||||||
Photos copyright by Jay Graham Photographer
